Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human mutations that confer paclitaxel resistance.

Molecular cancer therapeutics - 1 Feb 2010

Yin Shanghua, Bhattacharya Rajat, Cabral Fernando

Abstract excerpt

The involvement of tubulin mutations as a cause of clinical drug resistance has been intensely debated in recent years. In the studies described here, we used transfection to test whether beta1-tubulin mutations and polymorphisms found in cancer patients are able to confer resistance to drugs that target microtubules. Three of four mutations (A185T, A248V, R306C, but not G437S) that we tested caused paclitaxel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to CHO Cells
Share to Cricetinae

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Mitosis

Share to Paclitaxel

Share to Tubulin

Share to Vinblastine

Source

Open in PubMed Open full text

Identifiers

PMID: 20103599
DOI: 10.1158/1535-7163.MCT-09-0674
PMCID: PMC2820594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human mutations that confer paclitaxel resistance.PMID 20103599Read ↗

Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.Semantic proximity Read ↗

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.Semantic proximity Read ↗

Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.Semantic proximity Read ↗

Paclitaxel resistance in cells with reduced beta-tubulin.Semantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.Semantic proximity Read ↗

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic ManipulationSemantic proximity Read ↗

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.Semantic proximity Read ↗

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Semantic proximity Read ↗

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.Semantic proximity Read ↗

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.Semantic proximity Read ↗

Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.